In the early morning of May 25, Beijing time, FTSE Russell, the world’s second largest index company, announced the first batch of A-shares included in its index system. The list covers the large, mid and small-cap stocks, and a total of 1,097 A shares were included, including Joincare Pharmaceutical Group and Livzon Pharmaceutical Group.

FTSE Russell is a wholly-owned subsidiary of the London Stock Exchange and the second largest index service provider in the world. Currently, approximately $16 trillion of assets are based on the FTSE Russell Index. The FTSE GEIS index system is divided according to two dimensions: market and market value. The market dimension can be subdivided into developed markets, emerging markets (subdivided into advanced emerging and secondary emerging), and frontier markets. The market value dimensions include large, mid, small and micro caps.

It is understood that scale, liquidity and growth are the main evaluation criteria for FTSERussell “A Inclusion”. In March of this year, MSCI official website information shows that Joincare Pharmaceutical Group and Livzon Pharmaceutical Group are expected to be included into the MSCI China constituent stocks. This time, Joincare＆Livzon Pharmaceutical Group are once again included into FTSE GEIS, indicating that their comprehensive strength are recognized again and such high-quality enterprises that are in line with the national industrial strategy and have good growth will become one of the main beneficiaries of this “A inclusion”.

Mai Siping, CEO of FTSERussell, said earlier that from the perspective of inclusion proportion, after the completion of three steps in the first phase, A shares will account for 5.57% of the FTSE Russell emerging market, and the first phase of “FTSE inclusion” will bring $10 billion net passive capital inflows. The passive capital inflows in June 2019, September 2019 and March 2020 are expected to be $2 billion, $4 billion and $4 billion respectively.

 Article reprinted from: Financial Report